Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Marcel Reiser"'
Autor:
Gerhard Held, Martin H. J. Wiesen, Norbert Schmitz, Niels Murawski, Evelyn Kuhnt, Samira Zeynalova, Viola Poeschel, Carsten Müller, Marcel Reiser, Michael Pfreundschuh, Tanja Rixecker, Carsten Zwick
Publikováno v:
Blood. 123:640-646
To determine the effect of gender on outcome, the male hazard ratio for progression-free survival (HRPFS-male) was determined in patients with diffuse large B-cell lymphoma (DLBCL). In young patients (MapThera International Trial study), HRPFS-male w
Autor:
Roland Schroers, Agnieszka Korfel, Eckhard Thiel, Jan Eucker, Mathias Hänel, Peter Martus, Uwe Schlegel, Alexander Röth, Christian Scholz, Thomas Elter, Robert Möhle, Gerald Illerhaus, Martin Dreyling, Bernd Metzner, Josef Birkmann, Lars Fischer, Marcel Reiser
Publikováno v:
Haematologica. 98:364-370
The prognosis of patients with central nervous system relapse of aggressive lymphoma is very poor with no therapy established so far. In a prospective multicenter phase II study, we evaluated a potentially curative chemotherapy-only regimen in these
Autor:
Hans Theodor Eich, Martina Heimann, Rolf-Peter Müller, Hartmut Stützer, Marcel Reiser, Jan Kriz
Publikováno v:
Strahlentherapie und Onkologie. 185:288-295
Retrospective analysis of therapy results in patients with stage I–II and limited stage III nodal low-grade non-Hodgkin’s lymphoma (NHL). The present retrospective study covers 65 patients treated between 1988 and 2006 at the Department of Radiat
Autor:
S. Schmitz, Georg Hess, Bernd Metzner, Wolfram Klapper, Marcel Reiser, Ullrich Graeven, Michael Kneba, Joerg Thomas Bittenbring, Wolfgang Hiddemann, Karin Hohloch, Christian Buske, Hartmut Eimermacher, Hannes Wandt, Eva Hoster, W.-D. Ludwig, Bernhard J. Woermann, R. Fuchs, Martin Dreyling, Michael Unterhalt, J. Schimke
Publikováno v:
Leukemia. 23:153-161
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of
Autor:
Michael Kneba, Michael Pfreundschuh, Bernd Metzner, Marcel Reiser, Lorenz Trümper, Markus Loeffler, Bertram Glass, Marita Kloess, Nobert Schmitz M.D., Bernd Dörken, Wolfgang E. Berdel
Publikováno v:
Cancer. 106:136-145
BACKGROUND Patients with aggressive lymphoma and high-risk features at the time of diagnosis are reported to have a poor prognosis with standard therapy. Attempts to improve the results achieved with the combination of cyclophosphamide, doxorubicin,
Publikováno v:
British Journal of Haematology. 122:413-423
The granulopoiesis-stimulating factors, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), are used to prevent neutropenia and febrile neutropenia in patients with malignant lymphoma. The ques
Autor:
Jan Oliver Staak, Konrad Müller-Hermelink, Ute Rehwald, Holger Schulz, Christoph Driessen, Volker Diehl, Marcel Reiser, Franck Morschhauser, Andreas Engert, M. Sieber, Thomas Rüdiger
Publikováno v:
Blood. 101:420-424
This phase 2 trial was performed to evaluate the safety and efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20+ subtypes of Hodgkin disease (HD). Eligibilit
Autor:
Juergen Wolf, Marcel Reiser, U. Rueffer, Hans Tesch, PD Wickramanayake, Andreas Josting, Diehl, D. Söhngen, Andreas Engert, Andreas Draube
Publikováno v:
Leukemia & Lymphoma. 37:115-123
We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autolo
Autor:
Christoph Scheid, Andreas Draube, D. Söhngen, Hans Tesch, Markus Y. Mapara, Volker Diehl, Marcel Reiser, J. Wolf, Andreas Josting, J. Chemnitz, Andreas Engert
Publikováno v:
Bone Marrow Transplantation. 23:1223-1228
High-dose chemotherapy (HDCT) followed by autologous blood stem cell transplantation is considered the treatment of choice for patients with relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). However, several aut
Autor:
S. Bamborschke, R. Lehrke, R. Schröder, B. Salzberger, Hans Tesch, Volker Diehl, Marcel Reiser, Gerd Fätkenheuer, Daniel Re
Publikováno v:
Journal of Infection. 38:26-29
Two cases of opportunistic cerebral infections in HIV-negative cancer patients due to chemotherapy induced immunosuppression are reported. A 61-year-old patient with low grade lymphoma (immunocytoma as referred to the Kiel classification) developed s